Skip to content

Study · Randomized controlled trial · n = 1,991 · 2022

6 results

Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).

Unger J, Allison DC, Kaltoft M, Lakkole K, Panda JK, Ramesh C, Sargin M, Smolyarchuk E, Twine M, Wolthers B, Yarimbas G, Zoghbi M

Diabetes, obesity & metabolism18 Oct 2021Cited by 9 (Europe PMC)

PMID34622567 (opens in a new tab)PMCIDPMC9298244 (opens in a new tab)DOI10.1111/dom.14566 (opens in a new tab)PepBankPUB-34622567
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on metformin, median time to inadequate glycaemic control was 44 weeks longer with liraglutide than with an oral antidiabetic drug.

    In plain wordsIn adults with type 2 diabetes on metformin, blood sugar stayed controlled 44 weeks longer with liraglutide than with an added tablet.

    Peptide
    Liraglutide
    Outcome
    IncreaseTime to inadequate glycaemic control (HbA1c >7.0%)
    Study

    n = 1,991

    Comparator
    Oral antidiabetic drug (OAD) added to metformin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Measurements

    Median time to inadequate glycaemic control
    109 weeks
    liraglutide
    Median time to inadequate glycaemic control
    65 weeks
    OAD

    Source sentences

    Summary
    Median time to inadequate glycaemic control was 44 weeks longer with liraglutide versus OAD (109 weeks [25% percentile, 38; 75% percentile, not available] vs. 65 weeks [25% percentile, 35; 75% percentile, 107], P < .0001).
    2 context sentences
    Summary · context
    Primary endpoint: time to inadequate glycaemic control (HbA1c > 7.0%) at two scheduled consecutive visits after week 26.
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on metformin, HbA1c change at week 104 or at premature discontinuation significantly favoured liraglutide over an oral antidiabetic drug.

    In plain wordsIn adults with type 2 diabetes on metformin, HbA1c change favoured liraglutide over an added tablet.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedHbA1c change at week 104 or premature discontinuation
    Study

    n = 1,991

    Comparator
    Oral antidiabetic drug (OAD) added to metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in HbA1c and body weight at week 104 or at premature treatment discontinuation significantly favoured liraglutide over OAD
    1 context sentence
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on metformin, body weight change at week 104 or at premature discontinuation significantly favoured liraglutide over an oral antidiabetic drug.

    In plain wordsIn adults with type 2 diabetes on metformin, body weight change favoured liraglutide over an added tablet.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBody weight change at week 104 or premature discontinuation
    Study

    n = 1,991

    Comparator
    Oral antidiabetic drug (OAD) added to metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in HbA1c and body weight at week 104 or at premature treatment discontinuation significantly favoured liraglutide over OAD.
    1 context sentence
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes uncontrolled on metformin, hypoglycaemia rates were comparable between liraglutide and oral antidiabetic drugs.

    In plain wordsIn adults with type 2 diabetes on metformin, low blood sugar rates were similar with liraglutide and with an added tablet.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia rate
    Study

    n = 1,991

    Comparator
    Oral antidiabetic drug (OAD) added to metformin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemia rates were comparable between groups
    1 context sentence
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes uncontrolled on metformin, few patients stopped because of adverse events: 7.9% with liraglutide and 4.1% with oral antidiabetic drugs.

    In plain wordsIn adults with type 2 diabetes on metformin, few people stopped because of side effects: 7.9% with liraglutide and 4.1% with an added tablet.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiscontinuation because of adverse events
    Study

    n = 1,991

    Comparator
    Oral antidiabetic drug (OAD) added to metformin
    Outcome group
    Adverse events · Whole body
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Measurements

    Discontinuation due to adverse events
    7.9%
    liraglutide
    Discontinuation due to adverse events
    4.1%
    OAD

    Source sentences

    Summary
    few patients discontinued because of adverse events (liraglutide, 7.9% [n = 79]; OAD, 4.1% [n = 41]).
    1 context sentence
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In a post hoc analysis, results for liraglutide versus each individual oral antidiabetic drug class were similar to those for the pooled comparison.

    In plain wordsIn an extra analysis, liraglutide gave similar results against each single tablet class.

    Peptide
    Liraglutide
    Outcome
    IncreaseOutcomes versus individual oral antidiabetic drug classes (post hoc)
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors, DPP-4 inhibitors and sulphonylureas, each separately
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    up to 1.8 mg/d · up to 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar results were observed in the post hoc analysis for liraglutide versus individual OAD classes.
    1 context sentence
    Summary · context
    Adults (n = 1991) with T2D (HbA1c 7.5%-9.0%) receiving metformin were randomized 1:1 to liraglutide (≤1.8 mg/d) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.